Adam Płużański

机构：National Institute of Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology · ORCID：0000-0002-3710-6445

发表论文 120 篇 · 总被引 17322 次 · h-index 27

代表论文

• Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial (2023 · ESMO Open · 被引 51)
• Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis (2024 · Journal of Thoracic Oncology · 被引 29)
• Clinicopathological characteristics of patients with primary tracheal tumors: Analysis of eighty‐nine cases (2024 · Thoracic Cancer · 被引 10)
• Tracheal Tumors: Clinical Practice Guidelines for Palliative Treatment and Follow-Up (2024 · Oncology Reviews · 被引 6)
• Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study) (2024 · Current Oncology · 被引 6)
• Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050 (2024 · Future Oncology · 被引 5)